Time to Hit HIV, Early and Hard

Abstract

Early treatment of asymptomatic human immunodeficiency virus type 1 (HIV-1) infection remains controversial. In the AIDS Clinical Trials Group 019 study, zidovudine was shown in 1990 to slow the clinical progression to AIDS in infected but asymptomatic subjects.¹ However, a follow-up of those subjects found no evidence of longer survival with the use of zidovudine.² Furthermore, the Concorde study found that there was not only no survival benefit from early treatment with zidovudine, but also no effect on the overall progression of disease.³ Now, in this issue of the Journal, Volberding et al. report the further results of the AIDS . . .